Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Biochem ; 116(5): 787-96, 2015 May.
Article in English | MEDLINE | ID: mdl-25510836

ABSTRACT

Curcumin has therapeutic potential in preventing several types of cancer, including colon, liver, prostate, and breast. The goal of this study was to evaluate the chemopreventive activity of systemically administered curcumin on oral carcinogenesis induced by 4-nitroquinolone-1-oxide (4-NQO). A total of 50 male albino rats, Rattus norvegicus, (Holtzman), were divided into five groups (n = 10 per group). Four of these groups were exposed to 50 ppm 4-NQO in their drinking water ad libitum for 8 or 12 weeks, two groups were treated with curcumin by oral gavage at 30 or 100 mg/kg per day, and one group was treated with corn oil (vehicle) only. The negative control group was euthanized at baseline. Tongues of all animals were removed after euthanasia and used in the subsequent analysis because the tongue is the primary site of carcinogenesis in this model. Descriptive histological analysis and immunohistochemistry for PCNA, Bcl-2, SOCS1 e-3, and STAT3 were performed to assess the oncogenic process. The gene expression of Vimentin, E-cadherin, N-cadherin, or TWIST1 was assessed using RT-qPCR as a representative of epithelial-mesenchymal transition (EMT) events. The administration of curcumin at 100 mg/kg during the 12 weeks markedly decreased the expression of PCNA, Bcl-2, SOCS1 e -3, and STAT3. Curcumin also minimized the cellular atypia under microscopic analysis and diminished the expression of the genes associated with EMT. These findings demonstrate that the systemic administration of curcumin has chemopreventive activity during oral carcinogenesis induced by 4-NQO.


Subject(s)
Antineoplastic Agents/therapeutic use , Curcumin/therapeutic use , Mouth Neoplasms/prevention & control , 4-Nitroquinoline-1-oxide/metabolism , Animals , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/genetics , Carcinogens/metabolism , Corn Oil/therapeutic use , Curcumin/pharmacology , Disease Models, Animal , Epithelial Cells , Epithelial-Mesenchymal Transition/drug effects , Gene Expression/drug effects , Male , Mouth Neoplasms/chemically induced , Mouth Neoplasms/drug therapy , Quinolones/metabolism , Rats , Tongue/pathology
2.
Mediators Inflamm ; 2014: 959471, 2014.
Article in English | MEDLINE | ID: mdl-25104884

ABSTRACT

Tetracycline-based matrix metalloproteinase- (MMP-) inhibitors are currently approved for two inflammatory diseases, periodontitis and rosacea. The current study addresses the therapeutic potential of a novel pleiotropic MMP-inhibitor not based on an antibiotic. To induce experimental periodontitis, endotoxin (LPS) was repeatedly injected into the gingiva of rats on one side of the maxilla; the contralateral (control) side received saline injections. Two groups of rats were treated by daily oral intubation with a chemically modified curcumin, CMC 2.24, for two weeks; the control groups received vehicle alone. After sacrifice, gingiva, blood, and maxilla were collected, the jaws were defleshed, and periodontal (alveolar) bone loss was quantified morphometrically and by µ-CT scan. The gingivae were pooled per experimental group, extracted, and analyzed for MMPs (gelatin zymography; western blot) and for cytokines (e.g., IL-1ß; ELISA); serum and plasma samples were analyzed for cytokines and MMP-8. The LPS-induced pathologically excessive bone loss was reduced to normal levels based on either morphometric (P = 0.003) or µ-CT (P = 0.008) analysis. A similar response was seen for MMPs and cytokines in the gingiva and blood. This initial study, on a novel triketonic zinc-binding CMC, indicates potential efficacy on inflammatory mediators and alveolar bone loss in experimental periodontitis and warrants future therapeutic and pharmacokinetic investigations.


Subject(s)
Curcumin/analogs & derivatives , Curcumin/therapeutic use , Matrix Metalloproteinase Inhibitors/therapeutic use , Periodontal Diseases/drug therapy , Periodontitis/drug therapy , Animals , Lipopolysaccharides/pharmacology , Male , Periodontal Diseases/metabolism , Periodontal Diseases/pathology , Periodontitis/metabolism , Periodontitis/pathology , Rats
3.
Innate Immun ; 18(1): 155-63, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21242275

ABSTRACT

Curcumin is a plant-derived dietary spice ascribed various biological activities. Curcumin therapeutic applications have been studied in a variety of conditions, but not on periodontal disease. Periodontal disease is a chronic inflammatory condition initiated by an immune response to micro-organisms of the dental biofilm. Experimental periodontal disease was induced in rats by injecting LPS in the gingival tissues on the palatal aspect of upper first molars (30 µg LPS, 3 times/week for 2 weeks). Curcumin was administered to rats daily via oral gavage at 30 and 100 mg/kg body weight. Reverse transcriptase-qPCR and ELISA were used to determine the expression of IL-6, TNF-α and prostaglandin E(2) synthase on the gingival tissues. The inflammatory status was evaluated by stereometric and descriptive analysis on hematoxylin/eosin-stained sections, whereas modulation of p38 MAPK and NK-κB signaling was assessed by Western blot. Curcumin effectively inhibited cytokine gene expression at mRNA and protein levels, but NF-κB was inhibited only with the lower dose of curcumin, whereas p38 MAPK activation was not affected. Curcumin produced a significant reduction on the inflammatory infiltrate and increased collagen content and fibroblastic cell numbers. Curcumin potently inhibits innate immune responses associated with periodontal disease, suggesting a therapeutic potential in this chronic inflammatory condition.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Curcumin/administration & dosage , Gingiva/drug effects , Periodontal Diseases/drug therapy , Administration, Oral , Animals , Anti-Inflammatory Agents/adverse effects , Cell Movement/drug effects , Cell Movement/immunology , Curcumin/adverse effects , Disease Models, Animal , Down-Regulation/drug effects , Down-Regulation/immunology , Gingiva/immunology , Gingiva/metabolism , Gingiva/pathology , Humans , Interleukin-6/genetics , Interleukin-6/metabolism , Intramolecular Oxidoreductases/genetics , Intramolecular Oxidoreductases/metabolism , Lipopolysaccharides/immunology , Male , NF-kappa B/metabolism , Periodontal Diseases/immunology , Prostaglandin-E Synthases , Rats , Rats, Inbred Strains , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
4.
J Periodontol ; 82(5): 767-77, 2011 May.
Article in English | MEDLINE | ID: mdl-21073332

ABSTRACT

BACKGROUND: Platelets contain an array of biologic mediators that can modulate inflammation and repair processes including proinflammatory mediators and growth factors. Previous studies have shown that periodontitis and periodontal repair are associated with platelet activation. We hypothesized that drug-induced platelet inactivation may interfere in the processes of inflammation and repair in experimental periodontitis in rats by suppressing the release of biologic mediators from platelets to the site of injury. METHODS: To measure the effects on periodontitis, ligatures were placed around first molars, and aspirin (Asp, 30 mg/kg) or clopidogrel (Clo, 75 mg/kg) was given intragastrically once daily for 15 days. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and thromboxane A(2) levels were measured by enzyme-linked immunosorbent assay. To evaluate the effects of antiplatelet drugs on periodontal repair, ligatures were removed after 15 days of periodontitis induction, and Asp or Clo were administered beginning the following day for 15 days. Periodontal repair was assessed by microcomputed tomography. RESULTS: On periodontitis phase, Asp and Clo significantly reduced levels of TNF-α and Il-6 (P <0.05), but only Asp decreased thromboxane A(2) (P <0.05). Asp and Clo decreased inflammatory infiltration; however, this reduction was more pronounced with Clo treatment (P <0.05). Histometric analysis showed that Asp and Clo impaired alveolar bone resorption. During the repair phase and after removal of the ligatures, microcomputed tomography analysis demonstrated that treatment with Asp and Clo did not impair alveolar bone repair. CONCLUSION: Systemic administration of Asp and Clo attenuates the inflammation associated with periodontitis without affecting the repair process when stimulus is removed.


Subject(s)
Periodontitis/etiology , Periodontium/drug effects , Platelet Aggregation Inhibitors/therapeutic use , Alveolar Bone Loss/etiology , Alveolar Bone Loss/pathology , Alveolar Bone Loss/prevention & control , Animals , Aspirin/therapeutic use , Blood Platelets/drug effects , Bone Density/drug effects , Bone Regeneration/drug effects , Clopidogrel , Inflammation Mediators/analysis , Intercellular Signaling Peptides and Proteins/analysis , Interleukin-6/analysis , Leukocytes/drug effects , Male , Mandibular Diseases/etiology , Mandibular Diseases/pathology , Mandibular Diseases/prevention & control , Periodontal Attachment Loss/etiology , Periodontal Attachment Loss/pathology , Periodontal Attachment Loss/prevention & control , Periodontitis/pathology , Periodontitis/prevention & control , Periodontium/pathology , Platelet Activation/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley , Thromboxane A2/analysis , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use , Time Factors , Tumor Necrosis Factor-alpha/drug effects , Wound Healing/drug effects , X-Ray Microtomography
SELECTION OF CITATIONS
SEARCH DETAIL
...